Agilvax: AgilVax Triggers $2 Million Phase II Fast Track SBIR Grant and Initiates GMP Manufacturing
AgilVax Inc. a biotechnology company developing targeted antibodybased therapies for the treatment of various cancers including metastatic breast cancer MBC announced today that the company has triggered Phase II funding of $2...
Read full article »
Agilvax is a biotechnological company that focuses on the discovery and development of immunotherapies and targeted vaccines.
Read more